Humacyte Q2 revenue rises to $0.4 million; net loss narrows to $36.8 million
Humacyte reported second quarter 2026 total revenue of $0.4 million, up from $0.3 million a year earlier, and a net loss of $36.8 million, compared with $37.7 million in the prior-year quarter. For the six months, the company swung to a net loss of $54.4 million from net income of $1.5 million, mainly due to a non-cash remeasurement of its contingent earnout liability, which matters for shareholders because it shows how non-operating accounting items can outweigh operating results.
Key points
- Q2 2026 total revenue was $0.4 million versus $0.3 million in Q2 2025; contract revenue was zero after a prior-year research collaboration ended.
- Q2 2026 net loss was $36.8 million ($0.16 per share) versus $37.7 million ($0.24 per share) a year earlier.
- Six-month net loss was $54.4 million, compared with net income of $1.5 million in the first six months of 2025, driven by the non-cash remeasurement of the contingent earnout liability.
- Cash, cash equivalents and restricted cash were $80.3 million at June 30, 2026, after a June 2026 public offering that raised gross proceeds of $57.5 million.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.